SynthesisWorld journal of pediatrics : WJP2020
Risk factors for infantile hemangioma: a meta-analysis.
Synthesis in World journal of pediatrics : WJP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy and safety of pharmacologic, laser, and combination therapies for infantile hemangioma: a systematic review and network meta-analysis with evidence certainty assessment.Frontiers in pharmacology · 2026Pooled it
- Darbepoetin and Infantile Hemangioma in Premature Infants.Journal of clinical medicine · 2026Article
- Article
- Review
- Immune microenvironment of infantile hemangioma: cellular dynamics, molecular networks, and emerging immunomodulatory strategies.Frontiers in immunology · 2026Review
- Synchronous orbital and intracranial infantile hemangiomas: a case report and literature review.Frontiers in pediatrics · 2026Article
- Multisystem Infantile Hemangiomatosis with Cutaneous, Hepatic, and Splenic Involvement.Pediatric reports · 2025Article
- Unveiling Infantile Hemangiomas: A Comprehensive Study of Patterns, Presentations, and Complications.Dermatology practical & conceptual · 2025Article
- Clinical Insights into Risk Factors for Infantile Hemangioma and Propranolol Treatment Outcomes.Diagnostics (Basel, Switzerland) · 2025Article
- Impact of congenital heart disease on clinical outcomes of oral propranolol therapy for Infantile hemangiomas: a propensity score-matched analysis.BMC pediatrics · 2025Article
- Nanotechnology in Infantile Hemangioma Management.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- The Evaluation, Diagnosis, and Management of Infantile Hemangiomas-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Malignant and Benign Head and Neck Tumors of the Pediatric Age: A Narrative Review.Current pediatric reviews · 2025Review
- Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors.Frontiers in cell and developmental biology · 2025Review
- Decoding infantile hemangioma: cellular dynamics, molecular signals, and microenvironmental influences.Frontiers in oncology · 2025Review
- Optimizing Propranolol Therapy for Infantile Hemangiomas: The Role of the Multidisciplinary Team.Cureus · 2024Article
- Article
- Infantile hemangiomas: a dermatologist's perspective.European journal of pediatrics · 2024Review
- Infantile hemangioma: the common and enigmatic vascular tumor.The Journal of clinical investigation · 2024Review
- Clinical characteristics of infantile haemangioma in twins: a retrospective study.BMC pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInfantile hemangioma (IH) is one of the most common tumors in infants. Its pathogenesis is complex and poorly understood. The risk factors of IH have been extensively studied from clinical and epidemiological perspectives in recent years, but the conclusions in the literature reports are inconsistent. To provide a reference for the prevention of hemangioma, we conducted a meta-analysis of the published studies of potential risk factors for IH.
methodsThe Cochrane Library, Ovid, PubMed, and Web of Science databases were searched systematically. Log odds ratios (log ORs), logistic regression standard errors and 95% confidence intervals (CIs) were used to compare the correlation between IH and potential risk factors. Review Manager 5.3.3 was used for the statistical analysis.
resultsSix studies were included and 17 potential risk factors were eventually evaluated. P values < 0.05 were found for female gender (P < 0.01, OR 2.04, 95% CI 1.65-2.51), low birth weight (P < 0.01, OR 4.39, 95% CI 3.05-6.31), multiple gestation (P = 0.01, OR 2.39, 95% CI 1.21-4.71), preterm birth (P = 0.03, OR 2.37, 95% CI 1.07-5.23), progesterone therapy (P < 0.01, OR 2.73, 95% CI 2.12-3.51), and family history (P = 0.01, OR 1.98, 95% CI 1.16-3.38).
conclusionsThis meta-analysis revealed that risk factors, including female gender, low birth weight, multiple gestation, preterm birth, progesterone therapy, and family history may affect the occurrence of IH.
Indexed as
Identifiers
31853885What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.